Pulsed Field Ablation (PFA) System Market: Current Analysis and Forecast (2023-2030)

Pulsed field ablation (PFA) system is an innovative medical technology used for the treatment of various cardiac arrhythmias and other medical conditions. Unlike traditional ablation techniques that use thermal energy to create lesions on target tissues, PFA relies on the delivery of pulsed electric fields to achieve tissue ablation. The introduction of PFA systems represents a significant advancement in the field of electrophysiology and minimally invasive procedures. The pulsed field ablation (PFA) system has been gaining traction in the market due to several factors, such as increasing incidence of atrial fibrillation, advancements in technology, growing minimally invasive procedures, increasing awareness and diagnosis, rising healthcare expenditure, rising regulatory support, and surge in company collaborations & partnerships are leading drivers of pulsed field ablation (PFA) systems globally.

The Pulsed Field Ablation (PFA) Systems Market is expected to grow at a steady rate of around 25.1% owing to the rising geriatric population which is more prone to heart disorders. For instance, in October 2022, according to the World Health Organization, by 2050, the world's population of people aged 60 years and older will double to 2.1 billion. The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Several factors, including a surge in the incidence of cardiac and respiratory disorders, increasing awareness regarding cardiovascular disorders, and increased investments in cardiology departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with pulsed field ablation (PFA) systems has resulted in faster treatment procedures and better accuracy which is also driving this market of pulsed field ablation (PFA) systems at a steady rate.

Based on therapeutic areas, the market is segmented into cardiovascular disorders, oncological disorders, respiratory disorders, and others. The cardiovascular disorders segment held the maximum share in the global market of pulsed field ablation (PFA) systems in 2022 owing to the rising geriatric population which is more prone to heart disorders like atrial fibrillation. For instance, in August 2023, according to the National Institutes of Health, the prevalence of atrial fibrillation increases with age, with 5% of individuals over the age of 65 and 10% of those over the age of 80 having this condition. The market experienced significant growth due to the increasing demand for minimally invasive procedures. A family history of heart disease is also a propelling factor for this segment. Thus, among the therapeutic areas, the cardiovascular disorders segment held a significant share of the market in 2022.

Based on product components, the market is bifurcated into catheters and generators. The generators segment is expected to hold a significant share of the market in the forecast period owing to the better energy delivery precision by generators. For instance, in January 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE Field Ablation (PFA) System which has an advanced generator named FARASTAR PFA Generator which is designed for an easy three-button click to prepare, confirm and deliver therapy using bipolar & biphasic waveforms with proprietary pulses. Generators are essential components of PFA systems as they produce the pulsed electric fields required for tissue ablation. The advancements in generator technology, such as enhanced control mechanisms, and improved safety features, have contributed to the growing adoption of PFA systems for various medical procedures. Additionally, the expanding applications of PFA technology beyond cardiovascular diseases to other conditions such as cancer and neurological disorders have driven the demand for more advanced and versatile generators. Thus, amongst product components, the generators category is expected to witness a higher CAGR during the forecast period.

Based on the application area, the market is bifurcated into ablation and ablation & mapping. The ablation segment held the maximum share in the global market of pulsed field ablation (PFA) systems in 2022 owing to the desired controlled ablation provided by the device. The advantages of PFA such as improved precision, reduced collateral damage to surrounding tissues, and potentially shorter procedure times, have fueled the expansion of the ablation segment within the PFA system market. Thus, among the application areas, the ablation segment held a significant share of the market in 2022.

For a better understanding of the market adoption of pulsed field ablation (PFA) systems, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global pulsed field ablation (PFA) system market in the forecast period. The aging population in many APAC countries, combined with lifestyle factors, has resulted in a higher prevalence of cardiac arrhythmias and other conditions that can be treated using PFA systems. Several other factors such as a surge in the development of a wide range of pulsed field ablation (PFA) systems, enhanced accessibility, and diversified healthcare costs are driving the market's growth during the forecast period. There have been major awareness programs regarding cardiovascular disorders in the region. For instance, SEAHEARTS (WHO HEARTS package adaptation to South-East Asia Region) resonated with the World Heart Day 2023 theme 'Use Heart, Know Heart' and offered countries a roadmap to scale up their current situations of heart disorders. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Some of the major players operating in the market include Boston Scientific Corporation; Kardium; Abbott; Galvanize Therapeutics, Inc.; MIRAI MEDICAL; Pulse Biosciences, Inc.; AccuPulse Medical; Acutus Medical, Inc.; CathRx Ltd.; AccuPulse Medical.